Sue Yom | UCSF Health

Dr. Sue S. Yom

Claim this profile

University of California, San Francisco

Studies Squamous Cell Carcinoma
Studies Nasopharyngeal Carcinoma
10 reported clinical trials
20 drugs studied

Area of expertise

1Squamous Cell Carcinoma
Sue S. Yom has run 4 trials for Squamous Cell Carcinoma. Some of their research focus areas include:
p16 negative
Stage III
Stage I
2Nasopharyngeal Carcinoma
Sue S. Yom has run 3 trials for Nasopharyngeal Carcinoma. Some of their research focus areas include:
Stage III
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.
University Of California, San Francisco
Image of trial facility.
UCSF Medical Center-Mission Bay

Clinical Trials Sue S. Yom is currently running

Image of trial facility.

SBRT

for Adenoid Cystic Carcinoma

The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival. The name(s) of the study intervention involved in this study is: * Stereotactic Body Radiation Therapy (SBRT)
Recruiting1 award N/A13 criteria
Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting1 award Phase 2 & 321 criteria

More about Sue S. Yom

Clinical Trial Related3 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Sue S. Yom has experience with
  • Cisplatin
  • Nivolumab
  • Intensity-Modulated Radiation Therapy
  • Cetuximab
  • Intensity-Modulated Radiation Therapy (IMRT)
  • Miracle Fruit Placebo Cube

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Sue S. Yom specialize in?
Is Sue S. Yom currently recruiting for clinical trials?
Are there any treatments that Sue S. Yom has studied deeply?
What is the best way to schedule an appointment with Sue S. Yom?
What is the office address of Sue S. Yom?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security